

Listing and evaluation of the results

51396: Dr. Endre Mikus
LabMagister Training and Science Ltd.





Survey of 27 January 2023

Adviser: Prof. Dr. med. Kai Gutensohn
Werlhof-Institut
Schillerstr. 23
30159 Hannover

Tel.: +49 511 330599 10
Mail: k.gutensohn@werlhof-institut.de

217

Haematology 11 - Stem/Progenitor Cells (CD 34)

Analyte	Sample	Unit	Your value	Target value	TV-Type	Lower limit	Upper limit	Deviation	Z-Score	Meets criteria	
CD34+ Events	11	/µl	65.0	63.3	SV	50.6	76.0	2.7%	0,257	+	
	12		33.0	39.0	SV	31.2	46.8	-15.4%	-1,37	+	
Leucocytes	(1) 11	/µl	13394								
	(1) 12		11523								
CD45+ events (single platform)	(1) 11	/µl	13385								
	(1) 12		10853								
Viable CD45+ Events	(1) 11	/µl	13318								
	(1) 12		10809								
Viable CD34+ Events	11	/µl	61.0	60.8	SV	48.6	73.0	0.3%	0,033	+	
	12		32.0	37.3	SV	29.8	44.8	-14.2%	-1,34	+	
Viable CD34+ Events per viable CD45+ Events	(1) 11	%	0.450								
	(1) 12		0.300								

Analyte	Sample	Your unit	Stated value	Conversion factor	Method	Manufacturer	Device	Sample reception date	Sample processing date
CD34+ Events	11		65.0	1.00	222	BN	BN04	01/18/23	01/18/23
	12		33.0	1.00					
Leucocytes	11		13394	1.00	222	BN	BN04	01/18/23	01/18/23
	12		11523	1.00					
CD45+ events (single platform)	11		13385	1.00	222	BN	BN04	01/18/23	01/18/23
	12		10853	1.00					
Viable CD45+ Events	11		13318	1.00	222	BN	BN04	01/18/23	01/18/23
	12		10809	1.00					
Viable CD34+ Events	11		61.0	1.00	222	BN	BN04	01/18/23	01/18/23
	12		32.0	1.00					
Viable CD34+ Events per viable CD45+ Events	11		0.450	1.00	222	BN	BN04	01/18/23	01/18/23
	12		0.300	1.00					

(1) In general, no certificate is issued for this parameter in this EQA scheme.

Individual summary of results

51396: Dr. Endre Mikus
LabMagister Training and Science Ltd.

Survey of 27 January 2023



217

Haematology 11 - Stem/Progenitor Cells (CD 34)

CD34+ Events (/μl, N = 97)

Collective	Sample	Target value	Target range	Participants collective			Rate (%)	
				AVG	CV	Num.	Sam.	total
all methods	11	63.3	50.6 - 76.0	63.3	10.4	97	90.7	86.6
	12	39.0	31.2 - 46.8	39.0	11.2	97	89.7	


Rate of success: 86,6%



Leucocytes (/μl, N = 30)

Collective	Sample	Target value	Target range	Participants collective			Rate (%)	
				AVG	CV	Num.	Sam.	total
all methods	11			12130		30		
	12			9821		30		


Rate of success: 96,7%



CD45+ events (single platform) (/μl, N = 90)


Collective	Sample	Target value	Target range	Participants collective			Rate (%)	
				AVG	CV	Num.	Sam.	total
all methods	11			12126		90		
	12			9728		90		

Rate of success: 96,7%





Viable CD45+ Events (/μl, N = 97)								
Collective	Sample	Target value	Target range	Participants collective			Rate (%)	
				AVG	CV	Num.	Sam.	total
all methods	11			11614		97		
	12			9314		97		

Rate of success: 90,7%



Viable CD34+ Events (/μl, N = 99)									
Collective	Sample	Target value	Target range	Participants collective			Rate (%)		
				AVG	CV	Num.	Sam.	total	
all methods	11	60.8	48.6 - 73.0	60.8	10.1	99	90.9	84.8	
	12	37.3	29.8 - 44.8	37.3	10.6	99	89.9		

Rate of success: 84,8%



Viable CD34+ Events per viable CD45+ Events (% , N = 98)								
Collective	Sample	Target value	Target range	Participants collective			Rate (%)	
				AVG	CV	Num.	Sam.	total
all methods	11			0.528		98		
	12			0.403		98		

Rate of success: 83,7%

